Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Mark Peterson CPA who wrote (441)	1/20/1999 11:22:00 PM
From: Greg Jenkins	Respond to of 942

here are recent comments from AG Edwards: 12-7-98 Recent developement: We believe the newpaper article in the LA Times, which reviewed the plusses and minuses of the drug Rezulin and some key points about its review by the FDA, will not be significant to the operations of WLA. Included was the fact that 33 people have died who are on the drug. Basically, adverse effects from increased liver enzymes is well known and patients are monitored and treated appropriately. We would take advantage of any pressure on the shares. ------------------------------------------------------------------- AG Edwards has a buy/conservative rating on the stock with a price target of $95 There are additional comments as of 1-15-99 but I only have half the comments. I will put the complete text as soon as I can. Greg J.